Recently, the All-China Federation of Industry and Commerce released the list of the top 500 private enterprises in China in 2022, and the threshold for the top 500 private enterprises to enter this year reached 26.
367 billion yuan, an increase of 2.
866 billion yuan
over the previous year.
The total operating income of the top 500 private enterprises was 38.
32 trillion yuan, an increase of 9.
13%.
In the pharmaceutical manufacturing industry, according to the author's incomplete statistics, a total of 13 pharmaceutical companies broke through the siege and broke into the list
of China's top 500 private enterprises in 2022.
They are:
Yangtze River Pharmaceutical (116)
Yangtze River Pharmaceutical (116)
Neptune Group (155)
Neptune Group (155)
Correction of the pharmaceutical industry (159 people)
Correction of the pharmaceutical industry (159 people)
Weigao Group (197 employees)
Weigao Group (197 employees)
Kelun Pharmaceutical (263)
Kelun Pharmaceutical (263)
CSPC Pharmaceutical Holdings (268)
CSPC Pharmaceutical Holdings (268)
East China Medicine(326)
East China Medicine(326)
Tasly (338)
Tasly (338)
Shinwa Shōnen (357)
Shinwa Shōnen (357)
Qilu Pharmaceutical (371)
Qilu Pharmaceutical (371)
Zhifei Bio (391)
Zhifei Bio (391)
Jimin Credible (467)
Jimin Credible (467)
Changjiang Runfa (478)
Changjiang Runfa (478)
13 pharmaceutical companies shortlisted in the 2022 China Top 500 Private Enterprises List! (Image source: Pharmaceutical Network)
From the perspective of the provinces that have broken into the list of the top 500 private pharmaceutical companies, most of them are shandong, Zhejiang and Jiangsu provinces, which have reached 2, and 1 each in Guangdong Province, Jilin Province, Hebei Province, Jiangxi Province, Tianjin Municipality and Chongqing Municipality
.
From the perspective of industry operation indicators, the total operating income of the 13 pharmaceutical companies shortlisted reached 561.
498 billion yuan, the net profit after tax was 53.
756 billion yuan, the total assets were 604.
676 billion yuan, the total net assets were 336.
357 billion yuan, the net interest rate of assets reached 8.
89%, and the return on net assets was 15.
98%.
Among the 13 pharmaceutical companies, there are 4 enterprises with operating income of more than 50 billion yuan, namely Yangzijiang Pharmaceutical, Neptune Group, Amendment Pharmaceutical and Weigao Group
.
Among them, the revenue of Yangzijiang Pharmaceutical has exceeded the mark of 70 billion yuan, reaching 78.
553 billion yuan, followed by Neptune Group and Amendment Pharmaceutical, with revenue of 65.
535 billion yuan and 64.
644 billion yuan
respectively.
R&D is the foundation of enterprise survival and development, and it is also the source
of enterprise competitiveness.
In terms of R&D investment, the shortlisted 13 pharmaceutical companies attach great importance to the report shows that the pharmaceutical manufacturing industry is among the top ten industries that pay for foreign R&D funds such as universities and research institutes, accounting for 53.
85%
of the proportion of the top 500 enterprises in the industry.
According to the data disclosed in the 2021 annual reports of the major shortlisted pharmaceutical companies, in 2021, the opening year of the "14th Five-Year Plan", many pharmaceutical companies continue to increase investment in research and development and improve their innovation capabilities
.
For example, Kelun Pharmaceutical's R&D investment in 2021 reached 1.
8 billion yuan, accounting for more than 10% of the current operating income, and it is reported that the company's cumulative R&D investment since 2013 has exceeded 8.
5 billion yuan
.
CSPC's R&D investment in 2021 increased significantly, exceeding 3 billion yuan, an increase of 18.
8% year-on-year, reaching 3.
433 billion yuan
.
Qilu Pharmaceutical has also continued to invest heavily in research and development, with R&D investment reaching 3.
32 billion yuan
in 2021.
Environmental protection is the cornerstone of
enterprise survival and development.
Under the background that energy conservation and environmental protection have become a major theme of the manufacturing industry, most of the shortlisted private pharmaceutical companies have actively participated in the pollution prevention and control battle, and the number of participating enterprises has reached 12, accounting for 2.
82%
of the top 500 enterprises participating in the pollution imitation battle.
As we all know, pharmaceutical companies belong to the "big households" of water use, it is reported that in order to effectively implement the new concept of water-saving development and promote the green and sustainable development of enterprises, Qilu Pharmaceutical has taken a multi-pronged approach in recent years to strengthen water
conservation.
For example, through the construction of ground source heat pump system and air source heat pump system, so as to achieve the purpose of zero evaporation and zero water replenishment, strengthen control from the source, and widely equipped with efficient water-saving equipment, so as to achieve the purpose of
water saving.
THE GOVERNANCE OF VOCs is also a "big and difficult" problem
in the pharmaceutical manufacturing industry.
It is reported that Corning Biologics, invested by Kelun Pharmaceutical, has continued to increase investment in environmental protection, and after years of arduous exploration and verification, it has overcome the problems of VOCs governance that have plagued enterprises for a long time, greatly improved the governance level of wastewater, waste gas and bacteria residue, and walked out of the road
of green, low-carbon and environmentally friendly sustainable development.
